566 related articles for article (PubMed ID: 30990879)
41. Differential kinase activity of ACVR1 G328V and R206H mutations with implications to possible TβRI cross-talk in diffuse intrinsic pontine glioma.
Cao H; Jin M; Gao M; Zhou H; Tao YJ; Skolnick J
Sci Rep; 2020 Apr; 10(1):6140. PubMed ID: 32273545
[TBL] [Abstract][Full Text] [Related]
42. Oncohistone Mutations in Diffuse Intrinsic Pontine Glioma.
Zhang X; Zhang Z
Trends Cancer; 2019 Dec; 5(12):799-808. PubMed ID: 31813457
[TBL] [Abstract][Full Text] [Related]
43. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma.
Nikbakht H; Panditharatna E; Mikael LG; Li R; Gayden T; Osmond M; Ho CY; Kambhampati M; Hwang EI; Faury D; Siu A; Papillon-Cavanagh S; Bechet D; Ligon KL; Ellezam B; Ingram WJ; Stinson C; Moore AS; Warren KE; Karamchandani J; Packer RJ; Jabado N; Majewski J; Nazarian J
Nat Commun; 2016 Apr; 7():11185. PubMed ID: 27048880
[TBL] [Abstract][Full Text] [Related]
44. Developing H3K27M mutant selective radiosensitization strategies in diffuse intrinsic pontine glioma.
Parsels LA; Wahl DR; Koschmann C; Morgan MA; Zhang Q
Neoplasia; 2023 Mar; 37():100881. PubMed ID: 36724689
[TBL] [Abstract][Full Text] [Related]
45. Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics.
Hoffman LM; DeWire M; Ryall S; Buczkowicz P; Leach J; Miles L; Ramani A; Brudno M; Kumar SS; Drissi R; Dexheimer P; Salloum R; Chow L; Hummel T; Stevenson C; Lu QR; Jones B; Witte D; Aronow B; Hawkins CE; Fouladi M
Acta Neuropathol Commun; 2016 Jan; 4():1. PubMed ID: 26727948
[TBL] [Abstract][Full Text] [Related]
46. Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope?
Cohen KJ; Jabado N; Grill J
Neuro Oncol; 2017 Aug; 19(8):1025-1034. PubMed ID: 28371920
[TBL] [Abstract][Full Text] [Related]
47. Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease.
Qi J; Esfahani DR; Huang T; Ozark P; Bartom E; Hashizume R; Bonner ER; An S; Horbinski CM; James CD; Saratsis AM
Acta Neuropathol Commun; 2019 May; 7(1):75. PubMed ID: 31092287
[TBL] [Abstract][Full Text] [Related]
48. Noncoding RNAs as potential biomarkers for DIPG diagnosis and prognosis: XIST and XIST-210 involvement.
Velázquez-Flores MÁ; Rodríguez-Corona JM; López-Aguilar JE; Siordia-Reyes G; Ramírez-Reyes G; Sánchez-Rodríguez G; Ruiz Esparza-Garrido R
Clin Transl Oncol; 2021 Mar; 23(3):501-513. PubMed ID: 32661825
[TBL] [Abstract][Full Text] [Related]
49. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma.
Paugh BS; Broniscer A; Qu C; Miller CP; Zhang J; Tatevossian RG; Olson JM; Geyer JR; Chi SN; da Silva NS; Onar-Thomas A; Baker JN; Gajjar A; Ellison DW; Baker SJ
J Clin Oncol; 2011 Oct; 29(30):3999-4006. PubMed ID: 21931021
[TBL] [Abstract][Full Text] [Related]
50. Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma.
Carceller F; Fowkes LA; Khabra K; Moreno L; Saran F; Burford A; Mackay A; Jones DT; Hovestadt V; Marshall LV; Vaidya S; Mandeville H; Jerome N; Bridges LR; Laxton R; Al-Sarraj S; Pfister SM; Leach MO; Pearson AD; Jones C; Koh DM; Zacharoulis S
J Neurooncol; 2016 Aug; 129(1):109-21. PubMed ID: 27180091
[TBL] [Abstract][Full Text] [Related]
51. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
[TBL] [Abstract][Full Text] [Related]
52. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
DeWire M; Fuller C; Hummel TR; Chow LML; Salloum R; de Blank P; Pater L; Lawson S; Zhu X; Dexheimer P; Carle AC; Kumar SS; Drissi R; Stevenson CB; Lane A; Breneman J; Witte D; Jones BV; Leach JL; Fouladi M
J Neurooncol; 2020 Sep; 149(3):511-522. PubMed ID: 33034839
[TBL] [Abstract][Full Text] [Related]
53. Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells.
Wiese M; Hamdan FH; Kubiak K; Diederichs C; Gielen GH; Nussbaumer G; Carcaboso AM; Hulleman E; Johnsen SA; Kramm CM
Cell Death Dis; 2020 Aug; 11(8):673. PubMed ID: 32826850
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
Akamandisa MP; Nie K; Nahta R; Hambardzumyan D; Castellino RC
Neuro Oncol; 2019 Jun; 21(6):786-799. PubMed ID: 30852603
[TBL] [Abstract][Full Text] [Related]
55. A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets.
Zhu X; Lazow MA; Schafer A; Bartlett A; Senthil Kumar S; Mishra DK; Dexheimer P; DeWire M; Fuller C; Leach JL; Fouladi M; Drissi R
Acta Neuropathol Commun; 2021 Jan; 9(1):14. PubMed ID: 33431066
[TBL] [Abstract][Full Text] [Related]
56. Pontine gliomas a 10-year population-based study: a report from The Canadian Paediatric Brain Tumour Consortium (CPBTC).
Fonseca A; Afzal S; Bowes L; Crooks B; Larouche V; Jabado N; Perreault S; Johnston DL; Zelcer S; Fleming A; Scheinemann K; Silva M; Vanan MI; Mpofu C; Wilson B; Eisenstat DD; Lafay-Cousin L; Hukin J; Hawkins C; Bartels U; Bouffet E
J Neurooncol; 2020 Aug; 149(1):45-54. PubMed ID: 32632896
[TBL] [Abstract][Full Text] [Related]
57. Diffuse intrinsic pontine glioma (DIPG): A review of current and emerging treatment strategies.
Weisbrod LJ; Thiraviyam A; Vengoji R; Shonka N; Jain M; Ho W; Batra SK; Salehi A
Cancer Lett; 2024 May; 590():216876. PubMed ID: 38609002
[TBL] [Abstract][Full Text] [Related]
58. Live-cell single-molecule dynamics of PcG proteins imposed by the DIPG H3.3K27M mutation.
Tatavosian R; Duc HN; Huynh TN; Fang D; Schmitt B; Shi X; Deng Y; Phiel C; Yao T; Zhang Z; Wang H; Ren X
Nat Commun; 2018 May; 9(1):2080. PubMed ID: 29802243
[TBL] [Abstract][Full Text] [Related]
59. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.
Mueller S; Taitt JM; Villanueva-Meyer JE; Bonner ER; Nejo T; Lulla RR; Goldman S; Banerjee A; Chi SN; Whipple NS; Crawford JR; Gauvain K; Nazemi KJ; Watchmaker PB; Almeida ND; Okada K; Salazar AM; Gilbert RD; Nazarian J; Molinaro AM; Butterfield LH; Prados MD; Okada H
J Clin Invest; 2020 Dec; 130(12):6325-6337. PubMed ID: 32817593
[TBL] [Abstract][Full Text] [Related]
60. Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas.
Ehteda A; Khan A; Rajakumar G; Vanniasinghe AS; Gopalakrishnan A; Liu J; Tsoli M; Ziegler DS
Mol Cancer Ther; 2023 Dec; 22(12):1413-1421. PubMed ID: 37683275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
